Wire · opportunities
FDA Approves Belzutifan Plus Lenvatinib for Advanced Kidney Cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 September 2026 · Fusion42 review
The FDA approved the combination of belzutifan and lenvatinib for adults with advanced renal cell carcinoma with a clear cell component that progressed after PD-1 or PD-L1 inhibitor therapy, based on phase 3 LITESPARK-011 trial results showing improved progression-free survival and response rate versus cabozantinib.
This Wire brief sits within Fusion42's coverage of Biotech, and 8 sources have reported it between 24 Sep 2026 and 28 Sep 2026.
◆ ◆ The Wire takeaway
Kidney cancer drug developers should expect increased competition as the belzutifan-lenvatinib combo gains US market access against PD-1 resistant cases. This is your moment to evaluate or accelerate clearance pathways for combination therapies targeting similar resistant tumours.
◆ Coverage
8 sources · first reported 24 Sep 2026 · latest 28 Sep 2026
◆ Topics